Shares of InterMune vaulted Tuesday after the company scored an exclusive collaboration agreement with Swiss giant Roche for hepatitis C drugs.The companies said after the bell Monday that they plan to develop and commercialize products from InterMune’s HCV protease inhibitor program. The Brisbane, Calif., biotech said it will get a $60 million upfront payment and up to $470 million in milestones, including $35 million in the next year.
InterMune shares recently were up $4.40, or 26%, to $21.23, on volume of more than 2.5 million shares. Average daily volume is just 313,000 shares.
Sorry, the comment form is closed at this time.